CL2012002014A1 - Formulacion farmaceutica de liberacion modificada que contiene 30-70% del ester etilico del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz de hidroxipropilmetilcelulosa (hpmc) y un polimero enterico; metodo de tratamiento de un trastorno provocado por hiperexcitabilidad del sistema nervioso. - Google Patents

Formulacion farmaceutica de liberacion modificada que contiene 30-70% del ester etilico del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz de hidroxipropilmetilcelulosa (hpmc) y un polimero enterico; metodo de tratamiento de un trastorno provocado por hiperexcitabilidad del sistema nervioso.

Info

Publication number: CL2012002014A1
Authority: CL; Chile
Prior art keywords: retigabine; fluorobenzylamino; hyperexcitability; hpmc; phenyl
Prior art date: 2010-01-20

Application number

CL2012002014A

Other languages

English (en)

Spanish (es)

Inventor

Biljana Nadjsombati

Original Assignee

Valeant Pharmaceuticals Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-20

Filing date

2012-07-20

Publication date

2013-04-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47042234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002014(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-01-20 Priority claimed from US12/690,889 external-priority patent/US20100323015A1/en

2010-01-21 Priority claimed from US12/691,680 external-priority patent/US20100323016A1/en

2012-07-20 Application filed by Valeant Pharmaceuticals Int filed Critical Valeant Pharmaceuticals Int

2013-04-05 Publication of CL2012002014A1 publication Critical patent/CL2012002014A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2012002014A 2010-01-20 2012-07-20 Formulacion farmaceutica de liberacion modificada que contiene 30-70% del ester etilico del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz de hidroxipropilmetilcelulosa (hpmc) y un polimero enterico; metodo de tratamiento de un trastorno provocado por hiperexcitabilidad del sistema nervioso. CL2012002014A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12/690,889 US20100323015A1 (en)	2008-07-18	2010-01-20	Modified release formulation and methods of use
US12/691,680 US20100323016A1 (en)	2008-07-18	2010-01-21	Modified release formulation and methods of use

Publications (1)

Publication Number	Publication Date
CL2012002014A1 true CL2012002014A1 (es)	2013-04-05

Family

ID=47042234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012002014A CL2012002014A1 (es)	2010-01-20	2012-07-20	Formulacion farmaceutica de liberacion modificada que contiene 30-70% del ester etilico del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz de hidroxipropilmetilcelulosa (hpmc) y un polimero enterico; metodo de tratamiento de un trastorno provocado por hiperexcitabilidad del sistema nervioso.

Country Status (6)

Country	Link
EP (1)	EP2525660A4 (fr)
BR (1)	BR112012018173A2 (fr)
CL (1)	CL2012002014A1 (fr)
CO (1)	CO6592107A2 (fr)
EA (1)	EA201290663A1 (fr)
MX (1)	MX2012008475A (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1212831C (zh) *	2000-03-08	2005-08-03	Awd.药品股份有限两合公司	药物制剂
JP5563731B2 (ja) *	2003-09-26	2014-07-30	アルザ・コーポレーシヨン	オピオイドおよび非オピオイド鎮痛薬の制御放出製剤
BRPI0719590A2 (pt) *	2006-11-28	2014-01-21	Valeant Pharmaceuticals Int	Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
KR20110052641A (ko) *	2008-07-18	2011-05-18	베일언트 파마슈티컬스 인터내셔널	변형 방출형 제형 및 이의 이용 방법

2011
- 2011-01-18 BR BR112012018173A patent/BR112012018173A2/pt not_active IP Right Cessation
- 2011-01-18 EP EP11735033.0A patent/EP2525660A4/fr not_active Withdrawn
- 2011-01-18 MX MX2012008475A patent/MX2012008475A/es not_active Application Discontinuation
- 2011-01-18 EA EA201290663A patent/EA201290663A1/ru unknown
2012
- 2012-07-20 CL CL2012002014A patent/CL2012002014A1/es unknown
- 2012-08-17 CO CO12139907A patent/CO6592107A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
EA201290663A1 (ru)	2013-03-29
BR112012018173A2 (pt)	2017-08-29
EP2525660A4 (fr)	2013-08-07
MX2012008475A (es)	2013-11-01
CO6592107A2 (es)	2013-01-02
EP2525660A1 (fr)	2012-11-28

Similar Documents

Publication	Publication Date	Title
CL2011000109A1 (es)	2011-11-25	Formulacion farmaceutica que comprende 30-70% de etilester del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo anionico y un polimero enterico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso.
CL2014000630A1 (es)	2014-11-07	Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
ES2525918T3 (es)	2015-01-02	Proceso para la fabricación de Nicorandil
BR112013010288A2 (pt)	2016-09-20	método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado
CL2012001215A1 (es)	2012-08-03	Sistema de expresion de un vector que comprende un primer y un segundo cassete de expresion donde el primer cassete codifica una gtp-ciclohidrolasa (gch1) y el segundo codifica una tirosina hidrolasa; vector; celula hospedera; uso del vector para preparar medicamento para tratar enfermedad asociada con catecolamina.
BR112013020743A2 (pt)	2016-10-18	composições e métodos para a terapia e diagnóstico de influenza
PH12018501072A1 (en)	2019-01-28	Modified release orally administered amino acid formulations
BR112012014423A2 (pt)	2017-12-19	"sistema para a geração de uma cosntrução de um objeto de interesse, estação de trabalho médica, parelhos de aquisição de imagens médicas, método de geração de uma construção de um objeto de interesse e produto de programa de computador
MX347106B (es)	2017-04-12	Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
CR20110599A (es)	2012-02-09	Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
CL2009001215A1 (es)	2009-08-21	Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
WO2011101863A3 (fr)	2012-01-19	Compositions pharmaceutiques à libération prolongée de lacosamide
UY35091A (es)	2014-05-30	Formulaciones de liberacion modificada para oprozomib
BR112012017691A2 (pt)	2016-04-05	nova composição
MX393491B (es)	2025-03-21	Formulación farmacéutica para administración oral con tasa de disolución controlada, comprendiendo la preparación de perlas de liberación sostenida que contienen hidrocloruro de tamsulosina.
CL2012002560A1 (es)	2013-03-22	Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
CR20150297A (es)	2015-08-14	Producto de comicronización que comprende acetato de ulipristal
BR112014004635A2 (pt)	2017-03-14	sistema terapêutico transdérmico para cloridrato de ácido 5-aminolavulínico
BRPI0913391A2 (pt)	2015-11-24	processo e sistema que permitem a proteção de um fluxo de vídeo comprimido contra os erros que ocorrem durante uma transmissão
EP4349330A3 (fr)	2024-07-31	Procédé de traitement d'états liés au récepteur pgi2
CY1120016T1 (el)	2018-12-12	Φαρμακοτεχνικες μορφες οξικης κασποφουνγκινης
BR112017028224A2 (pt)	2018-09-11	composição, e, método para proteger um leitão contra uma doença associada a pestivírus.
ECSP13012603A (es)	2013-07-31	Nueva formulacion del cetp(1)
BR112012020223B8 (pt)	2021-05-25	pélete farmacêutico de fator de crescimento epidérmico administrável por via oral, uso e processo de preparação do mesmo, bem como cápsula compreendendo o referido pélete
CL2012002014A1 (es)	2013-04-05	Formulacion farmaceutica de liberacion modificada que contiene 30-70% del ester etilico del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz de hidroxipropilmetilcelulosa (hpmc) y un polimero enterico; metodo de tratamiento de un trastorno provocado por hiperexcitabilidad del sistema nervioso.